U.S. market Closed. Opens in 5 hours 52 minutes

TNGX | Tango Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue36.53M24.86M37.04M7.66M24.65M
Cost of Revenue2.42M4.03M1.97M1.62M32.27M
Gross Profit34.11M20.83M35.08M6.03M-7.62M
Operating Expenses150.70M135.93M95.23M59.86M7.15M
Selling, General & Admin35.50M30.02M17.60M9.87M7.54M
Research & Development115.20M105.91M77.64M49.99M32.27M
Other Operating Expenses5.94M2.95M247.00K120.00KN/A
Operating Income-114.17M-111.07M-58.19M-52.20M-15.16M
Other Expenses / Income5.94M2.95M247.00K228.00K1.07M
Before Tax Income-101.61M-108.12M-57.94M-51.97M-14.10M
Income Tax Expenses134.00K54.00K292.00K-108.00KN/A
Net Income-101.74M-108.18M-58.23M-51.86M-14.10M
Interest ExpensesN/A-2.95MN/AN/AN/A
Basic Shares Outstanding94.57M87.82M62.11M31.93M8.99M
Diluted Shares Outstanding94.57M87.82M62.11M31.93M8.99M
EBITDA-111.76M-111.07M-58.19M-51.48M-14.52M
EBITDA Margin-305.96%-446.79%-157.09%-672.44%-58.90%
EBIT-101.61M-111.07M-57.94M-51.97M-14.10M
EBIT Margin-278.18%-446.79%-156.43%-678.84%-57.18%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙